For Admin

Japanese

A Leading Company in Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

For Absorption

For Vaccination

For Nose-to-Brain

3D Nasal Cast Model

News

2025｜2024｜2023｜2022｜2021｜2020〜

May 1, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Mar 24, 2025

SNBL’s Subsidiary, SNLD, Announces its Abstract Accepted at the Upcoming 77th American Academy of Neurology (AAN) 2025 Annual Meeting

Nov 26, 2024

SNBL’s Subsidiary, Satsuma Pharmaceuticals Receives FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

Oct 31, 2024

SNBL’s Subsidiary Satsuma Pharmaceuticals Resubmits New Drug Application for STS101 for Acute Treatment of Migraine With or Without Aura

Jan 18, 2024

FDA Issues Complete Response Letter for Satsuma’s STS101